NCT06709872View on ClinicalTrials.gov

A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline from Stage I Invasive Ovarian Cancer

Active, not recruitingOBSERVATIONAL

Enrollment

400

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

September 3, 2029

Study Completion Date

September 3, 2029

Conditions

Stage I Ovarian CancerBorderline Ovarian Tumors

Trial Locations (1)

3000

UZ Leuven, Leuven

All Listed Sponsors

lead

KU Leuven

OTHER